HRP20160425T1 - Postupak za analizu metilacije - Google Patents
Postupak za analizu metilacije Download PDFInfo
- Publication number
- HRP20160425T1 HRP20160425T1 HRP20160425TT HRP20160425T HRP20160425T1 HR P20160425 T1 HRP20160425 T1 HR P20160425T1 HR P20160425T T HRP20160425T T HR P20160425TT HR P20160425 T HRP20160425 T HR P20160425T HR P20160425 T1 HRP20160425 T1 HR P20160425T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- oligonucleotide
- seq
- oligonucleotides
- damage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- 230000011987 methylation Effects 0.000 title claims 5
- 238000007069 methylation reaction Methods 0.000 title claims 5
- 238000004458 analytical method Methods 0.000 title claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 7
- 230000006378 damage Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- YYBBSAOIUBKHJT-UHFFFAOYSA-N 2,4-dioxo-1h-pyrimidine-5-sulfonic acid Chemical compound OS(=O)(=O)C1=CNC(=O)NC1=O YYBBSAOIUBKHJT-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Claims (6)
1. Postupak za analizu metilacije koji obuhvaća
a) tretiranje genomske cDNA s jednim ili više reagensa kako bi se prevelo nemetilirane citozinske baze u uracil sulfonat ili u drugu bazu koja se ponaša drugačije pri vezanju od citozina, dok metilirani citozin ostaje nepromijenjen;
b) amplificiranje tretirane DNA pomoću
i) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 5 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; i
ii) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 44 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri;
c) dedukciju prisutnosti ili odsutnosti metilacije CpG dinukleotida amplificiranih u koraku b) iz rezulata koraka b).
2. Postupak prema zahtjevu 1, naznačen time da amplifikacija u koraku b) postupka obuhvaća uporabu
i) najmanje jednog oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu izabranu iz grupe koja sadrži SEQ ID NO: 7 i 49-57, pri čemu su navedeni jedan ili više oligonukleotida prikladni za uporabu kao blokatori;
ii) najmanje jednog oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu izabranu iz grupe koja sadrži SEQ ID NO: 8 i 58-61, pri čemu su navedeni jedan ili više oligonukleotida prikladni za uporabu kao probe; i
iii) polimeraze, poželjno toplinski stabilne polimeraze.
3. Postupak prema zahtjevu 2, koji obuhvaća
a) uporabu oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu SEQ ID NO: 7 pod (i); i
b) uporabu oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu SEQ ID NO: 8 pod (ii).
4. Postupak detekcije i/ili klasifikacije staničnih proliferativnih poremećaja, koji obuhvaća:
a) tretiranje genomske cDNA s jednim ili više reagensa kako bi se prevelo nemetilirane citozinske baze u uracil sulfonat ili u drugu bazu koja se ponaša drugačije pri vezanju od citozina, dok metilirani citozin ostaje nepromijenjen;
b) amplificiranje tretirane DNA pomoću
i) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 5 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri; i
ii) oligonukleotida koji obuhvaća ili sadrži sekvencu definiranu SEQ ID NO: 44 ili njegova varijanta s 5'-terminalnim i/ili 3'-terminalnim izbacivanjem 1, 2, 3, 4 ili 5 nukleotida; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao primeri;
c) dedukciju prisutnosti ili odsutnosti metilacije CpG dinukleotida amplificiranih u koraku b) iz rezulata koraka b), pri čemu najmanje jedan od detektiranih i klasificiranih staničnih proliferativnih poremećaja, najmanje djelomično, se dobiva.
5. Postupak prema zahtjevu 4, naznačen time da amplifikacija u koraku b) postupka dodatno obuhvaća uporabu
i) oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu izabranu iz grupe koja sadrži SEQ ID NO: 7 i 49-57; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao blokatori; i
ii) oligonukleotida koji obuhvaća ili uglavnom sadrži sekvencu izabranu iz grupe koja sadrži SEQ ID NO: 8 i 58-61; pri čemu navedeni oligonukleotidi su prikladni za uporabu kao probe; i
iii) polimeraze, poželjno toplinski stabilne polimeraze.
6. Uporaba postupka prema zahtjevima 1-3 za otkriće markera metilacije, pri čemu je marker indikativan za nuspojave kod pacijenata ili pojedinaca, gdje navedene nuspojave pripadaju u najmanje jednu od sljedećih kategorija neželjene interakcije s lijekovima; bolesti raka; stanični proliferacijski poremećaji; karcinom debelog crijeva; karcinom jetre; CNS poremećaji, oštećenja ili bolesti; simptomi agresije ili poremećaja u ponašanju; kliničke, psihološke i socijalne posljedice oštećenja mozga; psihotični poremećaji i poremećaji ličnosti; demencija i / ili povezani sindromi; kardiovaskularne bolesti, poremećaji ili oštećenja; poremećaji, oštećenja ili bolest probavnog trakta; poremećaji, oštećenja ili bolesti dišnog sustava; lezije, upale, infekcije, imunitet i / ili konvalidacija; kvar, oštećenje ili bolest tijela kao abnormalnosti u razvojnom procesu; poremećaji, oštećenja ili bolest kože, mišića, vezivnog tkiva i kostiju; endokrini i metabolički poremećaji, oštećenja ili bolest; glavobolje ili seksualni poremećaji.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07109907 | 2007-06-08 | ||
| EP07110409 | 2007-06-15 | ||
| EP07113516 | 2007-07-31 | ||
| EP07114659 | 2007-08-21 | ||
| EP07114863 | 2007-08-23 | ||
| EP08150552 | 2008-01-23 | ||
| EP08151442 | 2008-02-14 | ||
| EP12164321.7A EP2479289B1 (en) | 2007-06-08 | 2008-06-06 | Method for methylation analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160425T1 true HRP20160425T1 (hr) | 2016-08-12 |
Family
ID=40094240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160425TT HRP20160425T1 (hr) | 2007-06-08 | 2016-04-21 | Postupak za analizu metilacije |
| HRP20200059TT HRP20200059T1 (hr) | 2007-06-08 | 2020-01-16 | Postupak za analizu metilacije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200059TT HRP20200059T1 (hr) | 2007-06-08 | 2020-01-16 | Postupak za analizu metilacije |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8623599B2 (hr) |
| EP (3) | EP3101141B1 (hr) |
| CY (1) | CY1118259T1 (hr) |
| DK (2) | DK2479289T3 (hr) |
| ES (2) | ES2769841T3 (hr) |
| HK (1) | HK1172656A1 (hr) |
| HR (2) | HRP20160425T1 (hr) |
| HU (1) | HUE028727T2 (hr) |
| LT (1) | LT3101141T (hr) |
| PL (1) | PL2479289T3 (hr) |
| SI (2) | SI3101141T1 (hr) |
| WO (1) | WO2008149237A2 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| JP2012506705A (ja) | 2008-10-27 | 2012-03-22 | キアジェン ゲイサーズバーグ インコーポレイテッド | 迅速に結果を得るハイブリッドキャプチャー法による分析およびシステム |
| JP5738278B2 (ja) * | 2009-05-01 | 2015-06-24 | キアジェン ゲイサーズバーグ インコーポレイテッド | 試料中のｒｎａスプライシング形態を検出するための非標的増幅法 |
| JP5826752B2 (ja) * | 2009-09-14 | 2015-12-02 | キアジェン ゲイサーズバーグ インコーポレイテッド | 細胞学用培地に固定された組織サンプルから核酸またはタンパク質を回収するための組成物および方法 |
| JP5702789B2 (ja) | 2009-09-23 | 2015-04-15 | コーニンクレッカ フィリップス エヌ ヴェ | 亜硫酸水素塩により媒介されるｄｎａの変換を監視する方法 |
| US9605303B2 (en) | 2010-01-29 | 2017-03-28 | Qiagen Gaithersburg, Inc. | Method of determining and confirming the presence of an HPV in a sample |
| ES2615728T3 (es) | 2010-01-29 | 2017-06-08 | Qiagen Gaithersburg, Inc. | Métodos y composiciones para una purificación y un análisis múltiple específico de secuencia de ácidos nucleicos |
| CA2799200A1 (en) | 2010-05-19 | 2011-11-24 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| US9725754B2 (en) * | 2010-07-29 | 2017-08-08 | Sean F. Boyle | Generic sample preparation |
| EP2678442B1 (en) | 2011-02-24 | 2019-01-16 | QIAGEN Gaithersburg, Inc. | Materials and methods for detection of hpv nucleic acid |
| CA3111723A1 (en) | 2012-01-30 | 2013-08-08 | Exact Sciences Development Company, Llc | Sulfonated small dna compositions and methods for sulfonating and desulfonating small dnas |
| WO2013138644A2 (en) * | 2012-03-15 | 2013-09-19 | New England Biolabs, Inc. | Methods and compositions for discrimination between cytosine and modifications thereof, and for methylome analysis |
| EP2746403A1 (de) | 2012-12-21 | 2014-06-25 | Life Science Inkubator GmbH & Co. KG | Verfahren zur Bestimmung des DNA-Methylierungsgrades |
| CA2901293A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Detection of bisulfite converted nucleotide sequences |
| DK4026917T5 (da) | 2014-04-14 | 2024-07-15 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Fremgangsmåde og kit til bestemmelse af cellers eller vævs død eller dna's vævs- eller celleoprindelse ved dna-methyleringsanalyse |
| JP6731942B2 (ja) * | 2014-12-19 | 2020-07-29 | エピゲノミクスアーゲー | ＣｐＧメチル化の検出方法及び癌の診断方法 |
| AU2016343937B2 (en) | 2015-10-30 | 2023-01-19 | Exact Sciences Corporation | Multiplex amplification detection assay and isolation and detection of DNA from plasma |
| CN108495937A (zh) * | 2015-11-27 | 2018-09-04 | 新加坡科技研究局 | 核酸甲基化的确定 |
| CN105506133A (zh) * | 2016-01-15 | 2016-04-20 | 武汉艾米森生命科技有限公司 | 用于检测sept9基因甲基化的组合物、试剂盒及方法 |
| KR102436270B1 (ko) | 2016-05-05 | 2022-08-25 | 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 | 메틸화된 dna 분석에 의한 폐 종양의 검출 |
| WO2018140781A1 (en) | 2017-01-27 | 2018-08-02 | Exact Sciences Development Company, Llc | Detection of colon neoplasia by analysis of methylated dna |
| CN107164524A (zh) * | 2017-06-27 | 2017-09-15 | 深圳市优圣康生物科技有限公司 | 用于基因甲基化检测的引物和探针、采样方法、试剂盒 |
| US20200165671A1 (en) * | 2017-07-13 | 2020-05-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detecting tissue-specific dna |
| US11466323B2 (en) | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| CN108048570A (zh) * | 2017-12-29 | 2018-05-18 | 韩林志 | 用于结直肠癌相关基因Septin9甲基化检测的引物对、试剂盒及方法 |
| CN110283913A (zh) * | 2019-07-21 | 2019-09-27 | 广州奥百阕谱生物科技有限公司 | Rassf1a基因甲基化状态检测试剂盒及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3525072A1 (de) | 1985-07-13 | 1987-01-22 | Basf Ag | Verfahren zur herstellung von ueber o,o'-methylenether verknuepften phenolharzen und deren verwendung |
| DE3924052A1 (de) | 1989-07-21 | 1991-01-24 | Bayer Ag | N- (indol-6-yl)-heterocyclen |
| CA2062918A1 (en) | 1991-04-01 | 1992-10-02 | Richard A. Carpenter | Method for operating a networked computer system to minimize data conversion overhead |
| EP0833319A3 (en) | 1993-01-21 | 2002-04-03 | Matsushita Electric Industrial Co., Ltd. | Disc-shaped recording medium |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| AU7829398A (en) | 1997-06-09 | 1998-12-30 | University Of Southern California | A cancer diagnostic method based upon dna methylation differences |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| US6277607B1 (en) | 1999-05-24 | 2001-08-21 | Sanjay Tyagi | High specificity primers, amplification methods and kits |
| DE19957827C2 (de) | 1999-11-25 | 2003-06-12 | Epigenomics Ag | Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche |
| DE10010280B4 (de) | 2000-02-25 | 2006-08-10 | Epigenomics Ag | Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben |
| DE10010282B4 (de) | 2000-02-25 | 2006-11-16 | Epigenomics Ag | Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben |
| DE10010281B4 (de) | 2000-02-25 | 2005-03-10 | Epigenomics Ag | Ligase/Polymerase-Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben |
| DE10029915B4 (de) | 2000-06-19 | 2005-06-16 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen |
| EP1352089B1 (en) | 2000-08-25 | 2006-12-06 | Lovelace Respiratory Research Institute | Nested methylation-specific polymerase chain reaction cancer detection method |
| JP2004516821A (ja) | 2000-09-01 | 2004-06-10 | エピゲノミクス アーゲー | ゲノムＤＮＡ上の、配列コンテクスト５−ＣｐＧ−３内の特定シトシンのメチル化度の定量方法 |
| DE10112515B4 (de) | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| US6927028B2 (en) | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
| DE10338308B4 (de) | 2003-08-15 | 2006-10-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in DNA |
| DE602004021192D1 (de) | 2003-10-09 | 2009-07-02 | Epigenomics Ag | Verbesserte bisulfitkonversion von dna |
| WO2007039101A1 (en) | 2005-09-30 | 2007-04-12 | Epigenomics Ag | Method for the quantification of nucleic acids, in particular bisulfite treated dna |
| US8679745B2 (en) | 2004-09-30 | 2014-03-25 | Epigenomics Ag | Method for providing DNA fragments derived from an archived sample |
| US7700282B2 (en) | 2004-10-11 | 2010-04-20 | Epigenomics Ag | Method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids |
| WO2006088978A1 (en) | 2005-02-16 | 2006-08-24 | Epigenomics, Inc. | Method for determining the methylation pattern of a polynucleic acid |
| US8129107B2 (en) | 2005-04-01 | 2012-03-06 | Epigenomics Ag | Bisulfite conversion of DNA |
| DK1871912T3 (da) * | 2005-04-15 | 2012-05-14 | Epigenomics Ag | Fremgangsmåde til bestemmelse af DNA-methylering i blod- eller urinprøver |
| CN107663538B (zh) | 2005-04-15 | 2022-03-18 | Epi基因组股份公司 | 分析细胞增殖性病症的方法和核酸 |
-
2008
- 2008-06-06 PL PL12164321.7T patent/PL2479289T3/pl unknown
- 2008-06-06 ES ES16163841T patent/ES2769841T3/es active Active
- 2008-06-06 DK DK12164321.7T patent/DK2479289T3/en active
- 2008-06-06 LT LTEP16163841.6T patent/LT3101141T/lt unknown
- 2008-06-06 EP EP16163841.6A patent/EP3101141B1/en active Active
- 2008-06-06 HU HUE12164321A patent/HUE028727T2/en unknown
- 2008-06-06 ES ES12164321T patent/ES2570828T3/es active Active
- 2008-06-06 EP EP12164321.7A patent/EP2479289B1/en active Active
- 2008-06-06 WO PCT/IB2008/002118 patent/WO2008149237A2/en active Application Filing
- 2008-06-06 SI SI200832109T patent/SI3101141T1/sl unknown
- 2008-06-06 SI SI200831602A patent/SI2479289T1/sl unknown
- 2008-06-06 US US12/451,943 patent/US8623599B2/en active Active
- 2008-06-06 DK DK16163841.6T patent/DK3101141T3/da active
- 2008-06-06 EP EP08789067A patent/EP2152902A2/en not_active Withdrawn
-
2012
- 2012-12-24 HK HK12113317.5A patent/HK1172656A1/zh unknown
-
2016
- 2016-04-21 HR HRP20160425TT patent/HRP20160425T1/hr unknown
- 2016-05-10 CY CY20161100391T patent/CY1118259T1/el unknown
-
2020
- 2020-01-16 HR HRP20200059TT patent/HRP20200059T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2479289T3 (pl) | 2016-10-31 |
| US20110009277A1 (en) | 2011-01-13 |
| SI3101141T1 (sl) | 2020-03-31 |
| CY1118259T1 (el) | 2017-06-28 |
| DK3101141T3 (da) | 2020-02-03 |
| EP2479289A2 (en) | 2012-07-25 |
| EP3101141A2 (en) | 2016-12-07 |
| LT3101141T (lt) | 2020-03-10 |
| EP2479289A3 (en) | 2013-06-19 |
| HUE028727T2 (en) | 2017-01-30 |
| WO2008149237A2 (en) | 2008-12-11 |
| EP3101141A3 (en) | 2017-01-11 |
| HRP20200059T1 (hr) | 2020-04-03 |
| WO2008149237A3 (en) | 2009-06-04 |
| EP2152902A2 (en) | 2010-02-17 |
| EP3101141B1 (en) | 2019-10-16 |
| DK2479289T3 (en) | 2016-05-02 |
| ES2769841T3 (es) | 2020-06-29 |
| HK1172656A1 (zh) | 2013-04-26 |
| SI2479289T1 (sl) | 2016-10-28 |
| EP2479289B1 (en) | 2016-04-06 |
| ES2570828T3 (es) | 2016-05-20 |
| US8623599B2 (en) | 2014-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160425T1 (hr) | Postupak za analizu metilacije | |
| Cutillas et al. | Trichuris suis and Trichuris trichiura are different nematode species | |
| Lu et al. | The goose genome sequence leads to insights into the evolution of waterfowl and susceptibility to fatty liver | |
| Krawetz et al. | A survey of small RNAs in human sperm | |
| Takahashi | Influence of bacteria on epigenetic gene control | |
| Chernyavskaya et al. | Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling | |
| US20090286753A1 (en) | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mrnas | |
| Song et al. | Variation in mitochondrial minichromosome composition between blood-sucking lice of the genus Haematopinus that infest horses and pigs | |
| EP1966390A1 (en) | Detection of tissue origin of cancer | |
| US20050123952A1 (en) | Methods of rapid detection and identification of bioagents using microRNA | |
| CN102628082B (zh) | 基于高通量测序技术进行核酸定性定量检测的方法 | |
| de Bello Cioffi et al. | Whole chromosome painting reveals independent origin of sex chromosomes in closely related forms of a fish species | |
| Turčeková et al. | Morphological and genetic characterization of Echinococcus granulosus in the Slovak Republic | |
| Singh et al. | Molecular phylogeny of Urosomoida agilis, and new combinations: Hemiurosomoida longa gen. nov., comb. nov., and Heterourosomoida lanceolata gen. nov., comb. nov.(Ciliophora, Hypotricha) | |
| Huang et al. | Identification of putative miRNAs from the deep-branching unicellular flagellates | |
| Li et al. | Morphological and molecular evidence for a new species of the genus Raphidascaris (Nematoda: Anisakidae) from marine fishes from the South China Sea | |
| Stenger et al. | Highly divergent 18S rRNA gene paralogs in a Cryptosporidium genotype from eastern chipmunks (Tamias striatus) | |
| Kapralova et al. | Patterns of miRNA expression in Arctic charr development | |
| Haddad et al. | miRNA target prediction might explain the reduced transmission of SARS-CoV-2 in Jordan, Middle East | |
| Lai et al. | Lycium barbarum polysaccharide modulates gut microbiota to alleviate rheumatoid arthritis in a rat model | |
| Lo et al. | Biological and biochemical modulation of DNA methylation | |
| CN108913777A (zh) | 诊断肿瘤的dna甲基化相关的标记物及其应用 | |
| Patel et al. | Ocimum basilicum miRNOME revisited: a cross kingdom approach | |
| Glossop et al. | DNA methylation profiling of synovial fluid FLS in rheumatoid arthritis reveals changes common with tissue-derived FLS | |
| Ye et al. | Defining endogenous barcoding sites for CRISPR/Cas9-based cell lineage tracing in zebrafish |